The preclinical discovery and development of molnupiravir for the treatment of SARS-CoV-2 (COVID-19)

References

• Wang W, Kaelber DC, Xu R , et al. Breakthrough SARS-CoV-2 infections, hospitalizations, and mortality in vaccinated patients with cancer in the us between december 2020 and november 2021. JAMA Oncol. 2022; 8:1299–1311. PMID: 35394485.
   Web of Science ®Google Scholar
• Suleyman G, Fadel R, Brar I, et al. Risk factors associated with hospitalization and death in COVID-19 breakthrough infections. Open Forum Infect Dis. 2022;9(5):ofac116. PMID: 35437511; PMCID: PMC8903475.
   PubMed Web of Science ®Google Scholar
• WHO. Coronavirus (COVID-19) data. [accessed 2022 July 12]. Available from: https://www.who.int/data#reports.
   Google Scholar
• Rosenberg ES, Holtgrave DR, Dorabawila V, et al. New COVID-19 cases and hospitalizations among adults, by vaccination status — new York, May 3–July 25, 2021. MMWR Morb Mortal Wkly Rep. 2021;70:1306–1311.
   PubMedGoogle Scholar
• Pagliano P, Sellitto C, Conti V, et al. Characteristics of viral pneumonia in the COVID-19 era: an update. Infection. 2021;49(4):607–616. PMID: 33782861; PMCID: PMC8006879.
   PubMed Web of Science ®Google Scholar
• Tenforde MW, Self WH, Adams K, et al. Association between mRNA vaccination and COVID-19 hospitalization and disease severity. JAMA. 2021 Nov 23 326(20): 2043–2054. PMID: 34734975; PMCID: PMC8569602• This study highlights the effectiveness of COVID-19 vaccination demonstrating a reduced rate of hospitalization for those receiving an mRNA vaccine
   PubMed Web of Science ®Google Scholar
• Costantino M, Sellitto C, Conti V, et al. Adverse events associated with BNT162b2 and AZD1222 vaccines in the real world: surveillance report in a single Italian vaccine center. J Clin Med. 2022;11(5):1408. PMID: 35268499; PMCID: PMC8911524.
   PubMed Web of Science ®Google Scholar
• Tiwari V, Beer JC, Sankaranarayanan NV, et al. Discovering small-molecule therapeutics against SARS-CoV-2. Drug Discov Today. 2020;25(8):1535–1544. PMID: 32574699; PMCID: PMC7305878.•• This is an interesting review on the activity of many compounds, which were developed for the treatment of other relevant viral infections
   PubMed Web of Science ®Google Scholar
• Jang WD, Jeon S, Kim S, et al. Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay. Proc Natl Acad Sci U S A. 2021;118(30):e2024302118. PMID: 34234012; PMCID: PMC8325362.
   PubMed Web of Science ®Google Scholar
• Johnson KA, Dangerfield T. Mechanisms of inhibition of viral RNA replication by nucleotide analogs. Enzymes. 2021;49:39–62. PMID: 34696838; PMCID: PMC8474024.
   PubMedGoogle Scholar
• Roy V, Agrofoglio LA. Nucleosides and emerging viruses: a new story. Drug Discov Today. 2022;27:1945–1953. PMC8856764. PMC8856764.
   PubMed Web of Science ®Google Scholar
• Picarazzi F, Vicenti I, Saladini F, et al. Targeting the RdRp of emerging RNA viruses: the structure-based drug design challenge. Molecules. 2020;25(23):5695. PMID: 33287144; PMCID: PMC7730706.
   PubMed Web of Science ®Google Scholar
• Pagliano P, Sellitto C, Scarpati G, et al. An overview of the preclinical discovery and development of remdesivir for the treatment of coronavirus disease 2019 (COVID-19). Expert Opin Drug Discov. 2022;17(1):9–18. PMID: 34412564; PMCID: PMC8425432
   PubMed Web of Science ®Google Scholar
• Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe covid-19 in outpatients. N Engl J Med. 2022;386(4):305–315.
   PubMed Web of Science ®Google Scholar
• Doi Y, Hibino M, Hase R, et al. A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19. Antimicrob Agents Chemother. 2020;64(12):e01897–20. PMID: 32958718; PMCID: PMC7674035.
   PubMed Web of Science ®Google Scholar
• AlQahtani M, Kumar N, Aljawder D, et al. Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease. Sci Rep. 2022;12(1):4925. PMID: 35322077; PMCID: PMC8943168.
   PubMedGoogle Scholar
• Lee -C-C, Hsieh -C-C, Ko W-C. Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent. Antibiotics (Basel). 2021;10(11):1294. PMID: 34827232; PMCID: PMC8614993.
   PubMed Web of Science ®Google Scholar
• Singh AK, Singh A, Singh R, et al. An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19. Diabetes Metab Syndr. 2022;16(2):102396. PMID: 35051686; PMCID: PMC8755553.
   PubMed Web of Science ®Google Scholar
• Debing Y, Neyts J, Delang L. The future of antivirals: broad-spectrum inhibitors. Curr Opin Infect Dis. 2015;28(6):596–602. PMID: 26524332.
   PubMed Web of Science ®Google Scholar
• Pradere U, Garnier-Amblard EC, Coats SJ, et al. Synthesis of nucleoside phosphate and phosphonate prodrugs. Chem Rev. 2014;114(18):9154–9218. Epub 2014 Aug 21. PMID: 25144792; PMCID: PMC4173794.
   PubMed Web of Science ®Google Scholar
• Khan S, Attar F, Bloukh SH, et al. A review on the interaction of nucleoside analogues with SARS-CoV-2 RNA dependent RNA polymerase. Int J Biol Macromol. 2021;181:605–611. Epub 2021 Mar 22. PMID: 33766591; PMCID: PMC7982646.
   PubMed Web of Science ®Google Scholar
• Vicenti I, Zazzi M, Saladini F. SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19. Expert Opin Ther Pat. 2021;31(4):325–337. PMID: 33475441; PMCID: PMC7938656. •• The review discusses accurately the activity of some compounds interacting with RpRd.
   PubMed Web of Science ®Google Scholar
• Jahnz-Wechmann Z, Framski GR, Januszczyk PA, et al. Base-modified nucleosides: etheno derivatives. Front Chem. 2016;4:19. PMID: 27200341; PMCID: PMC4848297.
   PubMed Web of Science ®Google Scholar
• Sangawa H, Komeno T, Nishikawa H, et al. Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrob Agents Chemother. 2013;57(11):5202–5208. PMID: 23917318; PMCID: PMC3811313.
   PubMed Web of Science ®Google Scholar
• Oestereich L, Lüdtke A, Wurr S, et al. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res. 2014;105:17–21. PMID: 24583123.
   PubMed Web of Science ®Google Scholar
• Shiraki K, Sato N, Sakai K, et al. Antiviral therapy for COVID-19: derivation of optimal strategy based on past antiviral and favipiravir experiences. Pharmacol Ther. 2022;235:108121. PMID: 35121001; PMCID: PMC8806403.
   PubMed Web of Science ®Google Scholar
• Lan SH, Lai CC, Chang SP, et al. Favipiravir-based treatment for outcomes of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. Expert Rev Clin Pharmacol. 2022;15:759–766. PMID: 35579014.
   PubMed Web of Science ®Google Scholar
• Chiu MN, Bhardwaj M, Sah SP. Safety profile of COVID-19 drugs in a real clinical setting. Eur J Clin Pharmacol. 2022;78(5):733–753. PMID: 35088108; PMCID: PMC8794611.
   PubMed Web of Science ®Google Scholar
• Hernandez-Santiago BI, Beltran T, Stuyver L, et al. Metabolism of the anti-hepatitis C virus nucleoside beta-D-N4-hydroxycytidine in different liver cells. Antimicrob Agents Chemother. 2004;48(12):4636–4642. PMID: 15561837.
   PubMed Web of Science ®Google Scholar
• Stuyver LJ, Whitaker T, McBrayer TR, et al. Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob Agents Chemother. 2003Jan;471:244–254. PMID: 12499198; PMCID: PMC149013
   PubMed Web of Science ®Google Scholar
• Pyrc K, Bosch BJ, Berkhout B, et al. Inhibition of human coronavirus NL63 infection at early stages of the replication cycle. Antimicrob Agents Chemother. 2006;50(6):2000–2008. PMID: 16723558; PMCID: PMC1479111.
   PubMed Web of Science ®Google Scholar
• Barnard DL, Hubbard VD, Burton J, et al. Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine. Antivir Chem Chemother. 2004;15(1):15–22.
   PubMedGoogle Scholar
• Reynard O, Nguyen XN, Alazard-Dany N, et al. Identification of a new ribonucleoside inhibitor of Ebola virus replication. viruses. 2015;7(12):6233-40. erratum in: viruses. Viruses. 2016;8(5):E137. PMID: 26633464; PMCID: PMC4690858.• An article demonstrating inhibitory activities of β-d-N4-hydroxycytidine against EBOV replication.
   PubMed Web of Science ®Google Scholar
• Ehteshami M, Tao S, Zandi K, et al. Characterization of β-d-N4-hydroxycytidine as a novel inhibitor of chikungunya virus. Antimicrob Agents Chemother. 2017;61(4):e02395–16. PMID: 28137799; PMCID: PMC5365705.
   PubMed Web of Science ®Google Scholar
• Urakova N, Kuznetsova V, Crossman DK, et al. β-d-N4-hydroxycytidine is a potent anti-alphavirus compound that induces a high level of mutations in the viral genome. J Virol. 2018 17;92(3): e01965–17. PMID: 29167335; PMCID: PMC5774879.
   PubMed Web of Science ®Google Scholar
• Song HD, Tu CC, Zhang GW, et al. Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proc Natl Acad Sci U S A. 2005;102(7):2430–2435. PMID: 15695582; PMCID: PMC548959.
   PubMed Web of Science ®Google Scholar
• Chan JF, To KK, Tse H, et al. Interspecies transmission and emergence of novel viruses: lessons from bats and birds. Trends Microbiol. 2013;21(10):544–555. PMID: 23770275; PMCID: PMC7126491.
   PubMed Web of Science ®Google Scholar
• Hart BJ, Dyall J, Postnikova E, et al. Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays. J Gen Virol. 2014;95(Pt 3):571–577. PMID: 24323636; PMCID: PMC3929173.
   PubMedGoogle Scholar
• Borbone N, Piccialli G, Roviello GN, et al. Nucleoside analogs and nucleoside precursors as drugs in the fight against SARS-CoV-2 and other coronaviruses. Molecules. 2021;26(4):986. PMID: 33668428; PMCID: PMC7918729.
   PubMed Web of Science ®Google Scholar
• Jordan PC, Stevens SK, Deval J. Nucleosides for the treatment of respiratory RNA virus infections. Antivir Chem Chemother. 2018;26:2040206618764483. PMID: 29562753; PMCID: PMC5890544.
   Google Scholar
• Brendish NJ, Clark TW. Antiviral treatment of severe non-influenza respiratory virus infection. Curr Opin Infect Dis. 2017;30(6):573–578. PMID: 29095723.
   PubMed Web of Science ®Google Scholar
• Santoro MG, Carafoli E. Remdesivir: from Ebola to COVID-19. Biochem Biophys Res Commun. 2021;538:145–150. PMID: 33388129; PMCID: PMC7836944.
   PubMed Web of Science ®Google Scholar
• Brown AJ, Won JJ, Graham RL, et al. Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase. Antiviral Res. 2019;169:104541.
   PubMed Web of Science ®Google Scholar
• Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2022;22:(2) 209–221. PMID: 34534511; PMCID: PMC8439621.•• No clinical benefit was observed from the use of remdesivir in patients who to hospital for a symptomatic COVID-19.
   PubMed Web of Science ®Google Scholar
• Shannon A, Selisko B, Le NT, et al. Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. Nat Commun. 2020;11(1):4682. PMID: 32943628; PMCID: PMC7499305.
   PubMed Web of Science ®Google Scholar
• Bosaeed M, Alharbi A, Mahmoud E, et al . Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial. Clin Microbiol Infect. 2022;28(4):602–608.
   PubMed Web of Science ®Google Scholar
• Kara A, Yakut S, Caglayan C, et al. Evaluation of the toxicological effects of favipiravir (T-705) on liver and kidney in rats: biochemical and histopathological approach. Drug Chem Toxicol. 2022;21:1–11. PMID: 35450509.
   Google Scholar
• Good SS, Westover J, Jung KH, et al. AT-527, a double prodrug of a guanosine nucleotide analog, is a potent inhibitor of SARS-CoV-2 in vitro and a promising oral antiviral for treatment of COVID-19. Antimicrob Agents Chemother. 2021;65(4):e02479–20. PMID: 33558299; PMCID: PMC8097421.
   PubMed Web of Science ®Google Scholar
• Apaydın ÇB, Çınar G, Cihan-Üstündağ G. Small-molecule Antiviral agents in ongoing clinical trials for COVID-19. Curr Drug Targets. 2021;22(17):1986–2005. PMID: 33588727.
   PubMed Web of Science ®Google Scholar
• Toots M, Yoon JJ, Cox RM, et al. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci Transl Med. 2019;11:(515) eaax5866. PMID: 31645453; PMCID: PMC6848974. •• The potential effectiveness of β-d-N4-Hydroxycytidine for monotherapy of seasonal and pandemic influenza virus infections is highlighted by this study.
   PubMed Web of Science ®Google Scholar
• Toots M, Yoon JJ, Hart M, et al. Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model. Transl Res. 2020;218:16–28. Epub 2019 Dec 25. PMID: 31945316; PMCID: PMC7568909. .
   PubMed Web of Science ®Google Scholar
• Agostini ML, Pruijssers AJ, Chappell JD, et al. Small-molecule antiviral β-d-N4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. J Virol. 2019;93(24):e01348–19. PMID: 31578288; PMCID: PMC6880162.
   PubMed Web of Science ®Google Scholar
• Kabinger F, Stiller C, Schmitzová J, et al. Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 2021;28:(9):740–746. Epub 2021 Aug 11. PMID: 34381216; PMCID: PMC8437801. •• The mechanism of molnupiravir activity against SARS-CoV-2 is well-described in this study.
   PubMed Web of Science ®Google Scholar
• Gordon CJ, Tchesnokov EP, Schinazi RF, et al. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J Biol Chem. 2021;297(1):100770. Epub 2021 May 11. PMID: 33989635; PMCID: PMC8110631.
   PubMed Web of Science ®Google Scholar
• Gordon CJ, Tchesnokov EP, Woolner E, et al. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. J Biol Chem. 2020;295(20):6785–6797. Epub 2020 Apr 13. PMID: 32284326; PMCID: PMC7242698.
   PubMed Web of Science ®Google Scholar
• Fung A, Jin Z, Dyatkina N, et al. Efficiency of incorporation and chain termination determines the inhibition potency of 2’-modified nucleotide analogs against hepatitis C virus polymerase. Antimicrob Agents Chemother. 2014Jul;58(7):3636–3645. Epub 2014 Apr 14. PMID: 24733478; PMCID: PMC4068585.
   PubMed Web of Science ®Google Scholar
• Sheahan TP, Sims AC, Zhou S, et al. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020;12(541):eabb5883. PMID: 32253226; PMCID: PMC7164393 .
   PubMed Web of Science ®Google Scholar
• Celik I, Tallei TE. A computational comparative analysis of the binding mechanism of molnupiravir’s active metabolite to RNA-dependent RNA polymerase of wild-type and Delta subvariant AY.4 of SARS-CoV-2. J Cell Biochem. 2022;123(4):807–818. PMID: 35132671.
   PubMed Web of Science ®Google Scholar
• Wahl A, Gralinski LE, Johnson CE, et al . SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature. 2021;591(7850):451–457.
   PubMed Web of Science ®Google Scholar
• Rosenke K, Hansen F, Schwarz B, et al. Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model. Nat Commun. 2021 Apr 16;12(1):2295. PMID: 33863887; PMCID: PMC8052374.
   PubMed Web of Science ®Google Scholar
• Abdelnabi R, Foo CS, Kaptein SJF, et al. Molnupiravir (EIDD-2801) inhibits SARS-CoV2 replication in Syrian hamsters model. bioRxiv. 2020 cited 9 August 2022 From: https://www.biorxiv.org/content/10.1101/2020.12.10.419242v1.full.pdf
   Google Scholar
• Cox RM, Wolf JD, Plemper RK. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat Microbiol. 2021;6(1):11–18. PMID: 33273742; PMCID: PMC7755744
   PubMed Web of Science ®Google Scholar
• Vangeel L, Chiu W, De Jonghe S, et al. Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern. Antiviral Res. : , 2022; 198:105252.
   PubMed Web of Science ®Google Scholar
• Nguyen NN, Houhamdi L, Hoang VT, et al. SARS-CoV-2 reinfection and COVID-19 severity. Emerg Microbes Infect. 2022;11(1):894–901. PMID: 35264078; PMCID: PMC8942490.
   PubMed Web of Science ®Google Scholar
• Li P, Wang Y, Lavrijsen M, et al. SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination. Cell Res. 2022;32(3):322–324. Epub 2022 Jan 20. PMID: 35058606; PMCID: PMC8771185.
   PubMed Web of Science ®Google Scholar
• Fiaschi L, Dragoni F, Schiaroli E, et al. Efficacy of licensed monoclonal antibodies and antiviral agents against the SARS-CoV-2 omicron sublineages BA.1 and BA.2. Viruses. 2022;14(7):1374. PMID: 35891355; PMCID: PMC9321742.
   PubMed Web of Science ®Google Scholar
• Lieber CM, Cox RM, Sourimant J, et al. SARS-CoV-2 VOC type and biological sex affect molnupiravir efficacy in severe COVID-19 dwarf hamster model. Nat Commun. 2022;13(1):4416. PMID: 35906230; PMCID: PMC9338273.
   PubMed Web of Science ®Google Scholar
• FitzGerald R, Dickinson L, Else L, et al . Pharmacokinetics of ß-d-N4-hydroxycytidine, the parent nucleoside of prodrug molnupiravir, in non-plasma compartments of patients with SARS-CoV-2 infection. Clin Infect Dis. 2022; 75: e525–e528.
   PubMed Web of Science ®Google Scholar
• Abdelnabi R, Foo CS, Kaptein SJF, et al . The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model. EBioMedicine. 2021; 72:103595.
   PubMed Web of Science ®Google Scholar
• Min L, Sun Q. A promising strategy against SARS-CoV-2: pyrimidine inhibitors synergize with nucleoside analogues. Signal Transduct Target Ther. 2022;7(1):88. : .
   PubMed Web of Science ®Google Scholar
• Schultz DC, Johnson RM, Ayyanathan K, et al. Constant S, Ferrer M, Thaiss CA, Frieman MB, Cherry S. Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2. Nature. 2022;604(7904):134–140. PMID: 35130559.
   PubMed Web of Science ®Google Scholar
• Wang X, Sacramento CQ, Jockusch S, et al. Combination of antiviral drugs inhibits SARS-CoV-2 polymerase and exonuclease and demonstrates COVID-19 therapeutic potential in viral cell culture. Commun Biol. 2022 Feb 22;5(1):154. PMID: 35194144; PMCID: PMC8863796.
   PubMed Web of Science ®Google Scholar
• Pagliano P, Scarpati G, Sellitto C, et al. Experimental Pharmacotherapy for COVID-19: the Latest Advances. J Exp Pharmacol. 2021;13:1–13. PMID: 33442304; PMCID: PMC7800714.
   PubMedGoogle Scholar
• Conti V, Corbi G, Sellitto C, et al. Effect of tocilizumab in reducing the mortality rate in COVID-19 patients: a systematic review with meta-analysis. J Pers Med. 2021 Jul 1;11(7):628. PMID: 34357095; PMCID: PMC8307114.
   PubMed Web of Science ®Google Scholar
• Pourkarim F, Pourtaghi-Anvarian S, Rezaee H. Molnupiravir: a new candidate for COVID-19 treatment. Pharmacol Res Perspect. 2022Feb;10(1):e00909. PMID: 34968008; PMCID: PMC8929331.
   PubMed Web of Science ®Google Scholar
• Conti V, Sellitto C, Torsiello M, et al. Identification of drug interaction adverse events in patients with COVID-19: a systematic review. JAMA Network Open. 2022;5(4):e227970. PMID: 35438752.
   PubMed Web of Science ®Google Scholar
• SK SR, Anuba P, Swetha B, et al. Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: a evidence-based review from six databases. Diabetes Metab Syndr. 2022;16(3):102451. PMID: 35279008; PMCID: PMC8898923.
   PubMed Web of Science ®Google Scholar
• Zhou S, Hill CS, Sarkar S, et al . β-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells. J Infect Dis. 2021;224(3):415–419.
   PubMed Web of Science ®Google Scholar
• Painter GR, Natchus MG, Cohen O, et al. Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19. Curr Opin Virol. 2021;50:17–22. PMID: 34271264; PMCID: PMC8277160.
   PubMed Web of Science ®Google Scholar
• Painter WP, Holman W, Bush JA, et al. Human Safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob Agents Chemother. 2021;65(5):e02428–20. PMID: 33649113; PMCID: PMC8092915.
   PubMed Web of Science ®Google Scholar
• Githaka JM. Molnupiravir does not induce mutagenesis in host lung cells during SARS-CoV-2 treatment. Bioinform Biol Insights. 2022;16:11779322221085077. PMID: 35342288; PMCID: PMC8950025.
   Web of Science ®Google Scholar
• Wallace KB, Bjork JA. Molnupiravir; molecular and functional descriptors of mitochondrial safety. Toxicol Appl Pharmacol. 2022;442:116003. Epub 2022 Mar 28. PMID: 35358570; PMCID: PMC8958731.
   PubMed Web of Science ®Google Scholar
• Khoo SH, Fitzgerald R, Fletcher T, et al. Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. J Antimicrob Chemother. 2021 Nov 12;76(12):3286–3295. PMID: 34450619; PMCID: PMC8598307.
   PubMed Web of Science ®Google Scholar
• Fischer WA 2nd, Eron JJJ, Holman W, et al. A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. Sci Transl Med. 2022;14(628):eabl7430. PMID: 34941423.
   PubMed Web of Science ®Google Scholar
• Jayk Bernal A, da Silva Mm G, Musungaie DB, et al. Molnupiravir for oral treatment of covid-19 in nonhospitalized patients. N Engl J Med. 2022 Feb 10;386(6):509–520. Epub 2021 Dec 16. PMID: 34914868; PMCID: PMC8693688.
   PubMed Web of Science ®Google Scholar
• Wen W, Chen C, Tang J, et al. Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis. Ann Med. 2022 Dec;54(1): 516–523. PMID: 35118917; PMCID: PMC8820829. • This meta-analysis investigated the efficacy of oral compounds as treatment of COVID-19.
   PubMed Web of Science ®Google Scholar
• Patel R, Kaki M, Potluri VS, et al. A comprehensive review of SARS-CoV-2 vaccines: pfizer, Moderna & Johnson & Johnson. Hum Vaccin Immunother. 2022;18(1):2002083. PMID: 35130825; PMCID: PMC8862159.
   PubMed Web of Science ®Google Scholar
• Pagliano P, Spera AM, Ascione T, et al. Infections causing stroke or stroke-like syndromes. Infection. 2020;48(3):323–332. PMID: 32239441.
   PubMed Web of Science ®Google Scholar
• Sabbatino F, Conti V, Franci G, et al. PD-L1 Dysregulation in COVID-19 Patients. Front Immunol. 2021;12:695242. PMID: 34163490; PMCID: PMC8215357•• This study demonstrates that mitochondrial toxicity is not a primary off target in the mechanism of cytotoxicity for either molnupiravir or its active metabolite NHC in the HepG2 cell line
   PubMedGoogle Scholar